Click here to load reader
View
228
Download
0
Embed Size (px)
Laporan Tahunan / Annual Report 2011
Kantor Pusat dan PabrikJalan Indofarma No.1Cikarang Barat - Bekasi 17530Telepon : (021) 8832 3971 / 75Faksimili : (021) 8832 3972 73Website : www.indofarma.co.ide-mail : [email protected]
Moving ForwardBeyond The Generic Innovation
Annual Report 2011
PT Indofarma (Persero) Tbk.
PT Indofarma (Persero) Tbk. l Annual Report 2011
1Laporan Tahunan | Annual Report 2011
Selama sepuluh tahun terakhir, INDOFARMA telah berkembang menjadi sebuah perusahaan terbuka yang profesional dengan membangun fondasi pertumbuhan yang kuat. INDOFARMA melakukan penerapan tata kelola perusahaan yang baik secara konsisten. Identifikasi dini terhadap risiko, keterbukaan informasi terhadap pemangku kepentingan, serta sistem pengawasan internal dan eksternal yang kompeten telah membantu INDOFARMA meminimalisasi risiko korporasi.
Manajemen rantai pasok telah membuahkan hasil. Efisiensi produksi telah ditingkatkan, dan distribusi dikembangkan. Pemetaan portofolio produk difokuskan dalam mendukung pemasaran.
Peran utama INDOFARMA sebagai pemimpin pasar obat generik diwujudkan dengan senantiasa menyediakan obat-obatan terjangkau bagi masyarakat. INDOFARMA akan terus menjaga komitmen kualitas pada pelanggan melalui pemastian tingkat kesetaraan hayati dengan produk inovator melalui uji Bioavailability dan Bioequivalence. INDOFARMA secara konsisten juga berkontribusi pada program pemasaran sosial obat generik.
Transformasi budaya yang menyeluruh dilakukan secara bertahap diarahkan untuk mampu membentuk budaya perusahaan yang lebih berorientasi pada penciptaan nilai korporasi.
Dengan didukung faktor-faktor fundamental tersebut, memasuki tahun 2011 INDOFARMA memulai era akselerasi pertumbuhan. Pengembangan INDOFARMA ke depan dilakukan dengan empat platform inovasi, yaitu Generic Based Product Range Development, Generic-Related Business, Nutraceuticals dan Cross-Boundaries Healthcare Industries. Hal ini dilakukan untuk memantapkan posisi INDOFARMA sebagai Top Generic Manufacturer saat ini menjadi Health Care Company dimana terjadi perubahan paradigma pengobatan dari kuratif dan rehabilitatif menjadi preventif dan promotif.
For the last decade, INDOFARMA has been emerging as a professional public listed company with a solid platform of growth. INDOFARMA has also been implementing Good Corporate Governance principles consistently, resulting in proper risk mitigation protocols, transparancy to stakeholders and competence audit system. These results have further leveraged INDOFARMA in achieving business growth and minimized corporate risk.
In addition, the implementation of supply chain management practices has significantly resulted is better changes for the companys performance. Production efficiency has been improved over the years and distribution channels had been revitalized to enhance companys achievements.
The main role of INDOFARMA as the generic market leader has been materialized by consistently opening access to medicine for general public. INDOFARMA is committed to providing quality products to its customers through Bioavailability and Bioequivalency (bio level assesment using innovator product as the reference). In addition, INDOFARMA continuously contributes to social marketing program of its generic product.
Culture transformation has been taking place through out the organization in several stages focusing on building a value creation orientation in the corporate culture.
With these fundamental factors, INDOFARMA is confident in starting the year 2011 as the year of growth acceleration. The future development of INDOFARMA is based on four platforms of innovation, namely Generic Based Product Range Development, Generic-Related Business, Nutraceuticals and Cross-Boundaries Healthcare Industries. With these platforms, INDOFARMA is aimed to be a Health Care Company which transforms from its current position as Top Generic Manufacturer by significantly shifting the paradigm, from curative and rehabilitative into a preventive and promotive.
Moving ForwardBeyond The Generic Innovation
Generic Based Product Range Development
Nutraceuticals
OrganicGrowth
Un-OrganicGrowth
ProductBased
Development
BusinessBased
Development
Generic-Related Business
Cross-Boundaries Healthcare Industries
Top GenericManufacturer
HealthcareCompany
Innovation Platforms
1Laporan Tahunan | Annual Report 2011
2 Laporan Tahunan | Annual Report 2011
Ikhtisar KeuanganFinancial Highlight 4
Penghargaan & Sertifikasi Awards & Certification 8
Laporan Dewan Komisaris Report of Board of Commisioners 9
Profil Dewan Komisaris Board of Commisioners Profile 11
Laporan Direksi Report of Board of Directors 12
Profil DireksiBoard of Directors Profile 14
Profil PerusahaanCompany Profile 15
Peristiwa Penting 2011Important Events 2011 22
Jejak LangkahMilestones 23
Tinjauan Sumber Daya ManusiaReview of Human Resources 26
Tinjauan Bisnis PerusahaanReview of Enterprise Business 29
Tinjauan Hasil UsahaReview of Business Results 38
Tata Kelola PerusahaanGood Corporate Governance 44
Tanggung Jawab Sosial PerusahaanCorporate Social Responsibility 66
Pandangan StakeholdersStakeholders View 70
Laporan Keuangan Konsolidasian yang Berakhir pada 31 Desember 2011 dan 2010Consolidated Financial Statements for The Years Ended 31st Desember 2011 and 2010 73
Daftar IsiContent
3Laporan Tahunan | Annual Report 2011
Laporan Tahunan 2011 ini dibuat berdasarkan laporan keuangan Perseroan yang telah diaudit oleh KAP Husni, Muharam & Rasyidi. Laporan keuangan ini menggunakan standar akuntansi keuangan yang berlaku umum di Indonesia dan disajikan berdasarkan peraturan Badan Pengawas Pasar Modal dan Lembaga Keuangan No. VIII.G.7 dan VIII.G.2.Dalam laporan tahunan ini kata "INDOFARMA", "Perseroan", "Perusahaan", dan "Kami" merujuk kepada PT INDOFARMA (Persero) Tbk dan anak perusahaan yang dikonsolidasikan.Beberapa angka tertentu (termasuk persentase) telah dibulatkan untuk mempermudah pembacaan, sehingga angka, perhitungan, persentase dan rasio yang diberikan dengan yang sesungguhnya terdapat perbedaan.Laporan Tahunan ini memuat informasi keuangan, proyeksi, strategi, serta data historis. Pernyataan yang bersifat proyeksi mengandung risiko dan ketidakpastian.Untuk informasi lebih lanjut mengenai INDOFARMA silahkan menghubungi Hubungan Investor: Kantor Komersial, Jl. Tambak No. 2, Manggarai - Jakarta Pusat 13150, Indonesia. Telp.: (+62-21-85908350), Faks.: (+62-21-8574503), E-mail: [email protected] Versi online dokumen ini dapat dilihat pada situs kami http://www.indofarma.co.id
This Annual Report 2011 is based on audited financial statements of Husni, Muharam & Rasyidi Registered Public Accountant. These financial statements is using accounting standards are generally accepted in Indonesia and Presented based on the regulation of the Capital Market Supervisory Agency and Financial Institution No. VIII.G.7 and VIII.G.2.In this annual report the words "Indofarma", "Perseroan", "Company", and "we" refers to the PT Indofarma (Persero) Tbk and its subsidiaries which are consolidated.Some specific figures (including percentages) have been rounded for ease of reading, so the figures, calculations, percentages and ratios given by the real may slightly different.This Annual Report contains financial information, projections, strategies, as well as historical data. Some projections may contain risks and uncertainties.For more information on Indofarma please contact Investor Relations: Commercial Office, Jl. Tambak No. 2, Manggarai - Central Jakarta 13150, Indonesia, phone: (+62-21-85908350), fax: (+62-21-8574503), e-mail: [email protected] The online version of this document can be see on our website at http://www.indofarma.co.id
4 Laporan Tahunan | Annual Report 20114 Laporan Tahunan |Annual Report 2011
Dalam Jutaan Rupiah Kecuali Disebutkan Lain In Million Rupiah Otherwise Stated
Laporan Laba Rugi 2011 2010 2009 2008 2007 Income Statement
Penjualan Bersih 1.203.467 1.047.918 1.125.055 1.478.585 1.273.162 Net Sales
Harga Pokok Penjualan 807.283 729.454 820.420 1.145.182 983.208 Cost of Goods Sold
Laba Kotor 396.184 318.464 304.636 333.403 289.954 Gross Profit
Laba Usaha 91.959 56.448 45.909 63.019 44.710 Operating Income
Laba (Rugi) Kurs (768) 96 2.721 (16.812) (1.869) Gain (Loss) on Foreign Exchange
Beban Bunga 21.277 24.806 35.342 30.270 16.116 Interest Expenses
Beban Pajak 18.283 7.862 10.540 4.834 10.997 Tax Expenses
Laba Bersih 36.919 12.547 2.126 5.032 11.077 Net Income
Laba Bersih Komprehensif 36.969 12.547 2.126 5.032 11.077 Comprehensive Net Income
Jumlah Saham Beredar (Juta Lembar) 3.099 3.099 3.099 3.099 3.099 Shares Outstanding (Million Sheets)
Laba Usaha per Saham (Rp) 29.67 18.21 14.81 20.33 14.43 Operating Profit per Share (Rp)
Laba Bersih per Saham (Rp) 11.93 4.05 0.69 1.62 3.57 Earnings per Share (Rp)
Laporan Posisi Keuangan 2011 2010 2009 2008 2007 Balance Sheet
Aset Lancar 706.558 582.999 583.441 843.316 899.307 Current Assets
Investasi Jangka Pendek 28 31 25 25 2.336 Short Term Investments
Aset Tidak Lancar 408.343 150.959 144.594 120.830 110.130 Non Current Assets
Jumlah Aset 1.114.902 733.958 728.035 964.144 1.009.438 Total Assets
Liabilitas Jangka Pendek 459.404 375.569 376.912 632.908 686.297 Current Liabilities
Liabilitas Jangka Panjang 46.304 47.120 52.400 34.640 31.580 Long Term Liabilities
Jumlah Liabilitas 505.708 422.690 429.313 667.548 717.874 Total Liabilities
Modal Kerja Bersih 247.155 207.430 2
